The effective dosage of a n3-LC-PUFA intervention (with n3 LC-PUFA-enriched yoghurt) on the modulation of cardiovascular risk factors and inflammatory biomarkers were determined.
Fifty three mildly hypertriacylglycerolemic subjects (TAG ≥ 150 mg/dL (1.7 mmol/L)) participated on the placebo-controlled, double-blind, parallel designed study. The subjects consumed placebo yoghurt (1), or n3 LC-PUFA-enriched yoghurt (0.8 g n3 LC-PUFA/d (2), 3 g n3 LC-PUFA/d (3)) for 10 weeks. Blood samples were taken at the beginning and at the end of the period. Parameters: * Blood lipids (total cholesterol, HDL, LDL, triacylglycerols) * Fatty acid distribution of plasma lipids (PL) and erythrocyte membranes (EM) * Concentrations of eicosanoids (PGs, HETEs) * Production of ex vivo stimulated cytokines by T cells * SNPs in the CD36 genotype
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
53
Group 1 (placebo) Group 2 (0.8 g n3 LC-PUFA/d in 125 g yoghurt) Group 3 (3 g n3 LC-PUFA/d in 200 g yoghurt)
University of Jena, Institute of Nutrition, Department of Nutritional Physiology
Jena, Germany
Blood lipids (total cholesterol, HDL, LDL, triacylglycerols)
change from baseline after 10 weeks Group 1: placebo Group 2: 0.8 g n3 LC-PUFA/125 g yoghurt per day Group 3: 3 g n3 LC-PUFA/200 g yoghurt per day
Time frame: change from baseline after 10 weeks
fatty acid distribution in plasma lipids and erythrocyte membranes, eicosanoids in plasma, production of ex vivo stimulated cytokines by T cells, SNPs on CD36 genotype
change from baseline after 10 weeks Group 1: placebo Group 2: 0.8 g n3 LC-PUFA/125 g yoghurt per day Group 3: 3 g n3 LC-PUFA/200 g yoghurt per day
Time frame: change from baseline after 10 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.